In patients:

• with ACS, who are initially treated with clopidogrel at presentation
• admitted with thrombotic event (e.g., stent thrombosis or ACS), who have been treated with clopidogrel
• who are known poor metabolizer of clopidogrel (e.g., CYP2C19 loss-offunction)

In patients:

• with intolerance or side effects, who have additional high-risk clinical or angiographic features for thrombotic events warranting completion of the prescribed course of DAPT
• admitted with thrombotic event (e.g., stent thrombosis or ACS), who have been treated with the initial P2Y12 receptor inhibitor agent
• Interactions between CYP3A inducers and ticagrelor which affect its pharmacodynamics

In patients:

• major bleeding complication that has resolved, who have additional high-risk clinical or angiographic features for thrombotic events, warranting completion of the prescribed course of DAPT
• clinically relevant nuisance bleeding that interferes with patient’s ability to continue with prasugrel or ticagrelor
• intolerance or side effects to prasugrel / ticagrelor in patients who do not have additional high-risk clinical or angiographic features for thrombotic events
• a new indication for requiring concurrent treatment with an oral anticoagulant